Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
Agenus announced an oversubscribed private placement raising $85 million upfront at a premium to market, with potential gross proceeds of up to $340 million including warrants. The financing provides cash runway through year-end 2031, earmarked to fund the ROBBIN Phase 3 registrational trial of neoadjuvant BOT+BAL in MSS colon cancer.
Key figures
- Deal Value Usd
- 340000000
- Offering Price
- 3.69
- Shares Offered
- 23035227
- Cash runway
- year-end 2031
- Upfront proceeds
- 85000000
- Warrant proceeds
- 255000000
- Phase3 enrollment
- 850
- Addressable market
- $7 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.